or Try an Advanced Search...

    Rna Interference Stocks List

    Symbol Grade Name % Change
    SLN F Silence Therapeutics Plc 10.82
    ARWR D Arrowhead Research Corporation -2.30
    ABUS D Arbutus Biopharma Corporation 0.58
    ALNY D Alnylam Pharmaceuticals, Inc. -0.80
    BNTC C Benitec Biopharma Limited -4.32
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Biopharmaceutical Gene Expression Hepatitis B RNA Amyloid Amyloidosis Biology Biotechnology Cholesterol Gene Silencing Huntington's Disease Hypercholesterolemia Liver Cancer Molecular Biology Small Interfering Rna Transthyretin Acid Acute Intermittent Porphyria Acute Lymphoblastic Leukemia Ai Technology

    Related ETFs - A few ETFs which own one or more of the above listed Rna Interference stocks.

    Symbol Grade Name Weight
    GNOM F Global X Genomics & Biotechnology ETF 8.02
    HRTS F Tema Cardiovascular and Metabolic ETF 7.62
    PBE D PowerShares Dynamic Biotech & Genome 4.78
    MNTL D Tema Neuroscience and Mental Health ETF 4.52
    MEDX F Horizon Kinetics Medical ETF 4.45
    View all Rna Interference ETFs...
    Compare ETFs
    Compare HRTS to MEDX Compare HRTS to MNTL Compare HRTS to PBE

        Rna Interference Stocks Recent News

        Date Stock Title
        Nov 20 SLN SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
        Nov 19 SLN Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
        Nov 19 SLN Top 3 Health Care Stocks You'll Regret Missing In Q4
        Nov 18 SLN Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
        Nov 18 ALNY Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis
        Nov 18 ALNY ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
        Nov 18 ARWR Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
        Nov 18 ARWR Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
        Nov 18 ALNY Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
        Nov 17 ALNY Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
        Nov 17 SLN Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations
        Nov 15 ABUS Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
        Nov 15 ABUS Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Biopharmaceutical Gene Expression Hepatitis B RNA Amyloid Amyloidosis Biology Biotechnology Cholesterol Gene Silencing Huntington's Disease Hypercholesterolemia Liver Cancer Molecular Biology Small Interfering Rna Transthyretin Acid Acute Intermittent Porphyria Acute Lymphoblastic Leukemia Ai Technology
        Rna Interference

        RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression or translation, by neutralizing targeted mRNA molecules. RNAi is a natural process in which small interfering RNA (siRNA), microRNA (miRNA), or short hairpin RNA (shRNA) molecules bind to specific mRNA molecules and either degrade them or inhibit their translation into proteins. RNAi is used in research, biotechnology, and medicine to silence the expression of specific genes.

        Browse All Tags